Health TrialsbyHealthPanel

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry

ConditionsBreast CancerHereditary Breast and Ovarian Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of Kansas Medical Center

About this trial

PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

ER/PR <10% and HER negative per current ASCO/CAP guidelines

Stages I-IV

Any age at diagnosis

Patient must be within 5 years of diagnosis

Disqualifiers

None

Trial population

Academic Center \& Community Clinics

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

3,000 Participants
are grouped into 2 trial groups
Group A: Triple Negative Breast Cancer patients
Group B: Germline HBOC Mutation Carriers

Trial outcomes

Primary outcomes

1

Prevalence of germline mutations (such as BRCA1/2 mutations) in patients with TNBC

Time frame
5 years
2

. Predictors of response to neo/adjuvant chemotherapy in patients with TNBC

Time frame
5 years
3

Long term Disease free and overall survival rates in TNBC patients treated with different systemic therapies

Time frame
10 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Kansas Medical Center

Lead sponsor

University of Kansas

Sponsor institution

Source ClinicalTrials.gov
Apply now